This Week In Huntington's Disease Research keeps you up-to-date on HDSA research activities, recently published work about Huntington’s disease, historical moments in HD research and more.

HDBuzz: Can vitamins be used to treat symptoms of HD?

Posted on May 19, 2022

Researchers in Spain are studying whether a combination of vitamins approved to treat a different brain disorder, biotin-thiamine responsive basal ganglia…

Read More

HDSA Awards Five Donald A. King Summer Research Fellowships

Posted on May 12, 2022

After extensive review by its Scientific Advisory Board, HDSA is excited to award the Donald A. King Summer Research Fellowship to five…

Read More


Posted on May 5, 2022

May is Huntington’s Disease Awareness Month, so #LetsTalkAboutHD. Post stories, videos, and photos to social media using #LetsTalkAboutHD. All stories…

Read More

Supporting people with HD: Researcher Spotlight on Leonard Sokol, MD

Posted on April 28, 2022

The field of HD research is constantly evolving as scientists inch closer to treatments and cures for people affected by HD. But…

Read More

Thank you, HD Research Volunteers!

Posted on April 21, 2022

This week, HDSA is celebrating National Volunteer Appreciation Week. This goes for research, too! We’d like to express our heartfelt…

Read More

Participate in research at the HDSA Center of Excellence at Rush University

Posted on April 14, 2022

A group of researchers at the HDSA Center of Excellence at Rush University are studying how the brains of people…

Read More

PTC Therapeutics initiates recruitment of PIVOT-HD study

Posted on April 7, 2022

Last week, PTC Therapeutics announced the initiation of their phase 2 clinical trial, PIVOT-HD, evaluating the effects of PTC518 in…

Read More

Upcoming Research Webinar: HDSA & the HD Research Pipeline Webinar April 6th

Posted on March 31, 2022

On April 6th at 12 PM ET, join HDSA’s Chief Mission Officer, Dr. Arik Johnson, and Assistant Director of Research and…

Read More

Happy World Social Work Month!

Posted on March 24, 2022

The month of March is a time to celebrate and appreciate social workers for all they do! Social workers help…

Read More

HDBuzz covers newly published research on branaplam

Posted on March 17, 2022

A study recently published in Nature detailed scientists’ understanding of how branaplam, a drug originally developed for treatment of spinal muscular atrophy…

Read More

The Editors of HDBuzz cover the CHDI Therapeutics Conference

Posted on March 10, 2022

For the first time in two years, scientists, clinicians, and industry partners convened in Palm Springs, CA for CHDI foundation’s 17th Annual HD Therapeutics Conference….

Read More

HDBuzz Covers the CHDI Conference

Posted on March 3, 2022

CHDI is a privately funded HD research foundation whose mission is to further development of HD therapies. This week, they’re hosting…

Read More

Raise Awareness of Rare Disease Day with HDSA February 28th

Posted on February 24, 2022

When you have a rare disease, you face two battles – one being the illness itself, and the other, living…

Read More

Quick Question: Genetic Testing and Rare Disease

Posted on February 17, 2022

Check out HDSA’s new short video series, “Quick Question,” in which HDSA’s Jennifer Simpson, LCSW (Assistant Director of Youth &…

Read More

A new mouse model for HD: The scoop from HDBuzz

Posted on February 10, 2022

Researchers at UCLA have developed a new mouse model for HD that more closely resembles human HD than ever before….

Read More

Splicing Modulators for HD: HDBuzz Covers PTC Therapeutics’ HTT-lowering approach

Posted on February 3, 2022

Huntingtin lowering (HTT-lowering) has been touted as a promising avenue for treatment of HD because it targets the cause of…

Read More

Update from Novartis on Planned Trial of Branaplam for Huntington’s Disease

Posted on January 27, 2022

Novartis is developing an experimental HD therapy called branaplam which has the potential to lower huntingtin when taken by mouth. Branaplam…

Read More

Roche to continue development of tominersen: Community Presentation TODAY

Posted on January 20, 2022

In a community letter released January 18th, Roche announced plans to continue developing the huntingtin-lowering drug tominersen. After analyzing data collected in the Phase III GENERATION HD-1 trial that halted dosing in…

Read More

Research Webinar: Roche Joins HDSA to Discuss Latest Data from GENERATION HD-1

Posted on January 13, 2022

One week from today, HDSA will be joined by members of the Roche team at 3:00 PM EST on January 20th for…

Read More

Upcoming Webinar: New Key Findings from the GENERATION HD-1 Study

Posted on January 6, 2022

Join HDSA at 3:00 PM EST on January 20th for an update from Roche on new findings from the data collected in the GENERATION HD-1 study. This…

Read More